Abstract:Background: Dry powder (DP) synthetic lung surfactant may be an effective means of noninvasive delivery of surfactant therapy to premature infants supported with nasal continuous positive airway pressure (nCPAP) in low-resource settings. Methods: Four experimental DP surfactant formulations consisting of 70% of phospholipids (DPPC:POPG 7:3), 3% Super Mini-B (SMB) or its sulfur-free derivate B-YL as SP-B peptide mimic, 25% of lactose or trehalose as excipient, and 2% of NaCl were formulated using spray drying. In vitro surface activity was confirmed with captive bubble surfactometry. Surfactant particle size was determined with a cascade impactor and inhaled dose was quantified using a spontaneously breathing premature lamb lung model supported with CPAP. In vivo surfactant efficacy was demonstrated in three studies. First, oxygenation and lung compliance were monitored after intratracheal instillation of resuspended DP surfactant in intubated, ventilated, lavaged, surfactant-deficient juvenile rabbits. In dose-response studies, ventilated, lavaged, surfactant-deficient rabbits received 30, 60, 120 or 240 mg/kg of DP B-YL:Lactose or B-YL:Trehalose surfactant by aerosol delivery with a low flow aerosol chamber via their endotracheal tube. Noninvasive aerosolization of DP B-YL:Trehalose surfactant via nasal prongs was tested in spontaneous breathing premature lambs supported with nCPAP. Intratracheal administration of 200 mg/kg of Curosurf®, a liquid porcine surfactant, was used as a positive control. Results: Mass median aerosol diameter was 3.6 μm with a geometric standard deviation of 1.8. All four experimental surfactants demonstrated high surface efficacy of intratracheal instillation of a bolus of ~ 100 mg/kg of surfactant with improvement of oxygenation and lung compliance. In the dose-response studies, rabbits received incremental doses of DP B-YL:Lactose or B-YL:Trehalose surfactant intratracheally and showed an optimal response in oxygenation and lung function at a dose of 120-240 mg/kg. Aerosol delivery via nasal prongs of 1 or 2 doses of ~ 100 mg/kg of B-YL:Trehalose surfactant to premature lambs supported with nCPAP resulted in stabilization of spontaneous breathing and oxygenation and lung volumes comparable to the positive control. Conclusion: These studies confirm the clinical potential of DP synthetic lung surfactant with B-YL peptide as a SP-B mimic to alleviate surfactant deficiency when delivered as a liquid bolus or as an aerosol.

Generation of novel trimeric fragments of human SP-A and SP-D after recombinant soluble expression in E. coli

A novel method of purifying lung surfactant proteins A and D from the lung lavage of alveolar proteinosis patients and from pooled amniotic fluid

[The Expression of Pulmonary Surfactant Proteins B and Surfactant Protein C in E. Coli].

Recombinant fragment of human surfactant protein D to prevent neonatal chronic lung disease (RESPONSE): a protocol for a phase I safety trial in a tertiary neonatal unit

A Combination of Short and Simple Surfactant Protein B and C Analogues as a New Synthetic Surfactant: In Vitro and Animal Experiments

“SP-G”, a Putative New Surfactant Protein – Tissue Localization and 3D Structure

New Surfactant with SP-B and C Analogs Gives Survival Benefit after Inactivation in Preterm Lambs

Developmental and genetic regulation of human surfactant protein B in vivo.

What is new in synthetic lung surfactant protein technology?

Transamniotic Delivery of Surfactant Protein B mRNA in a Healthy Model

Moving on from clinical animal-derived surfactants to peptide-based synthetic pulmonary surfactant

Porcine lung surfactant protein D: complementary DNA cloning, chromosomal localization, and tissue distribution

Characterization of Oligomer Formation of Surfactant Protein-D (SP-D) Using AF4-MALLS

The Coiled-Coil Neck Domain of Human Pulmonary Surfactant Protein D Drives Trimerization and Stabilization of Thioredoxin, a Heterologous Non-Collagenous Protein.

Early life surfactant protein-D levels in bronchoalveolar lavage fluids of extremely preterm neonates

Efficacy, dose-response, and aerosol delivery of dry powder synthetic lung surfactant treatment in surfactant-deficient rabbits and premature lambs

Expression and basic biochemical characteristics of recombinant surfactant protein D of bottlenose dolphin (Tursiopstruncatus)

Evolution of surfactant therapy for respiratory distress syndrome: past, present, and future

Evaluating Novel SP-B and SP-C Synthetic Analogues for Pulmonary Surfactant Efficacy

Surfactant Assisted Refolding of Recombinant Proteins

Development of a New Dry Powder Aerosol Synthetic Lung Surfactant Product for Neonatal Respiratory Distress Syndrome (RDS) - Part II: In vivo Efficacy Testing in a Rabbit Surfactant Washout Model